Participated · Series A · Feb 2026

Third Arc Bio, launched in 2022, focuses on creating multispecific antibodies that form immune synapses to either activate or inhibit T cells with high precision. Its lead program, ARC101, is a bispecific T-cell engager targeting CLDN6 and is currently in Phase 1 dose-escalation studies for patients with advanced solid tumors. The company’s solid-tumor ARCStim platform and immunology-focused ARCTag (Tethered Agonist) platform underpin a broader pipeline aimed at both cancer and immune-mediated disorders. By localizing immune modulation to sites of disease, Third Arc seeks to improve both efficacy and safety over conventional systemic therapies. The management team includes executives with prior drug-development track records, and a16z General Partner Jorge Conde recently joined the board. Financially, Third Arc Bio has secured at least $217 million in Series A funding (an initial $165 million plus a $52 million extension) in addition to earlier seed capital. Proceeds are earmarked to accelerate its immunology portfolio and advance additional oncology programs into the clinic.

Participated · Seed · Dec 2025

DISCO Pharmaceuticals is an oncology biotech leveraging a proprietary platform that maps the entire cell surface (the surfaceome) to uncover novel target pairs for drug development. Using these discoveries, the company engineers highly selective bispecific antibody-drug conjugates (ADCs) and T-cell engagers aimed at indications such as small cell lung cancer and microsatellite-stable colorectal cancer. The technology is designed to broaden the universe of actionable cancer targets and improve therapeutic precision. Recently, DISCO appointed veteran oncology executive Mark Manfredi, Ph.D., as CEO, while founder Roman Thomas, M.D., transitioned to a strategic advisor role. With a total of €36 million in seed capital, the company plans to move multiple lead ADC candidates into IND-enabling studies and to expand both indication-specific and pan-tumor programs. Investors believe the platform can unlock entirely new therapeutic areas by revealing previously unknown cell-surface biology. The fresh capital provides runway to advance the lead programs toward the clinic and continue generating additional surfaceome-based targets.

Participated · Series A · Jan 2025

Light Horse Therapeutics is a San Diego-based developer of small-molecule therapeutics. The company has built a proprietary platform that uncovers novel functional sites in disease-critical targets by integrating approaches and a precision genetic editing–based platform that interrogates proteins in their native environment. Its function-first discovery approach identifies novel functional domains before screening for chemistry, reversing traditional screening-first methodologies. The technology is intended to improve discovery of clinical candidates by revealing previously hidden functional domains. Light Horse says it will use proceeds from its recent financing to expand operations and advance its development efforts. The company is led by CEO Markus Renschler and its team includes CSO Laure Escoubet and scientific co-founders Brian Liau, Ben Cravatt and Nathanael Gray.

Led · Series A · Jul 2024

Oisín Biotechnologies is a privately held Seattle company developing genetic medicines to address age-related diseases using its Fusogenix Proteo-Lipid Vehicle (PLV) technology to deliver DNA directly to cells. Its lead programs focus on targeted fat reduction, muscle regeneration, and cellular senescence, with the fat reduction program delivering a fat‑killing genetic payload via direct injection to adipose tissue. A prior tolerability study in pigs demonstrated an excellent safety profile with no adverse effects or injection-site reactions. The company has been awarded a grant from the Methuselah Foundation to complete its first efficacy study in pigs, which will evaluate the efficacy and selectivity of two lead development candidates. The grant is described as a critical milestone in the company’s Series A workplan and support for advancing the program toward the clinic. Oisín says its technologies have attracted interest from leading pharmaceutical companies and advocacy groups, highlighting potential applicability across age-related conditions. Oisín Biotechnologies develops genetic medicines aimed at mitigating the effects of age-related diseases. The company utilizes the Fusogenix Proteo-Lipid Vehicle (PLV) delivery system developed by Entos Pharmaceuticals to deliver DNA directly to cells throughout the body. Its initial programs focus on eliminating unwanted fat cells and building muscle mass to address frailty. Oisín will use proceeds from its Series A financing to advance its pipeline toward clinical development. The company cites growing demand for therapies that address muscle loss associated with popular GLP-1 agonists. Oisín is headquartered in Seattle, Washington. Oisín Biotechnologies is a late preclinical biotechnology company focused on mitigating the effects of age-related diseases by clearing senescent cells. Its interventions are DNA-based and employ a proprietary SENSOlytics® proteo-lipid vehicle platform designed to induce apoptosis in senescent cells without harming healthy cells. In preclinical studies the company’s investigational therapeutics significantly reduced senescent cell burden in naturally aged mice and extended lifespan by more than 20%, even when treatment began in old age. The company’s most advanced program targets chronic kidney disease (CKD), with the OB-001 preclinical study readouts expected later this year. Oisín will use the new funding to advance its preclinical pipeline, progress additional indications, and move toward a regulatory filing to begin its first clinical trial. Headquartered in Seattle, the company says it will continue to explore other applications in tandem. The business completed an oversubscribed seed round raising $5 million, bringing total funding to $9.5 million.

Participated · Series C · Jan 2024

Accent Therapeutics develops small-molecule precision cancer therapies focused on critical intracellular dependencies across multiple cancer types. Led by CEO Shakti Narayan, the company leverages expertise in RNA-modifying proteins (RMPs) and systematic mapping of the RMP space and adjacent high-value areas to guide drug discovery. Its two lead programs are a first-in-class DHX9 inhibitor and a potentially best-in-class KIF18A inhibitor. The DHX9 program targets indications with high unmet need including BRCA loss-of-function cancers (breast, ovarian), mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) cancers (colorectal, endometrial, gastric) and additional undisclosed types. The KIF18A program could benefit patient populations across several indications including ovarian cancer and triple negative breast cancer (TNBC). The company plans to use the newly raised capital to advance both lead programs through early clinical development, including safety, pharmacokinetics and early efficacy studies. Accent Therapeutics develops oncology-focused small-molecule therapies that target RNA-modifying proteins (RMPs), an emerging field of post-transcriptional biology. Its lead programs are METTL3, an RNA methyltransferase implicated in AML, specific solid tumors and immuno-oncology, and ADAR1, an RNA editor with validation in subsets of solid tumors with elevated Type I interferon-stimulated gene signaling. The company applies enzyme-directed small-molecule approaches to RMPs to modulate RNA pathobiology. Since launching in 2018, Accent has advanced a broad pipeline of programs and aims to continue expanding in the RNA modification target space. Accent completed a $63 million Series B to advance its lead programs and broaden its pipeline. Proceeds from the financing will be used to advance development of METTL3 and ADAR1 and to continue pipeline expansion. Accent Therapeutics focuses on developing oncology-directed small-molecule therapies in the emerging field of epitranscriptomics, targeting RNA-modifying proteins (RMPs). The company aims to create a discovery platform and a pipeline of therapeutic candidates against RMPs linked to specific cancers. Accent raised $40 million in Series A capital to establish that discovery platform and advance its pipeline. Its leadership includes experienced drug developers and founders Howard Y. Chang (Stanford), Chuan He (University of Chicago) and Robert A. Copeland, who bring expertise in epitranscriptomics and drug discovery. The team has published a peer-reviewed overview of RMPs as anticancer drug targets in Nature Reviews Drug Discovery. Accent positions its programs to precisely target cancers that are uniquely dependent on particular RMPs.